Benitec Biopharma Stock (NASDAQ:BNTC)
Previous Close
$10.20
52W Range
$2.69 - $12.89
50D Avg
$8.90
200D Avg
$6.62
Market Cap
$103.55M
Avg Vol (3M)
$26.03K
Beta
0.90
Div Yield
-
BNTC Company Profile
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
ONCR | Oncorus, Inc. |
VIRI | Virios Therapeutics, Inc. |
NXTC | NextCure, Inc. |
APLM | Apollomics, Inc. |
BPTH | Bio-Path Holdings, Inc. |
CAPR | Capricor Therapeutics, Inc. |
DFFN | CervoMed Inc. |
LABP | Landos Biopharma, Inc. |
SGTX | Sigilon Therapeutics, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
CBIO | Gyre Therapeutics, Inc. |
ZURA | Zura Bio Limited |
ALRN | Aileron Therapeutics, Inc. |